Literature DB >> 25741163

Meta-analysis: is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection?

Zhi-Fa Lv1, Fu-Cai Wang1, Hui-Lie Zheng1, Ben Wang1, Yong Xie1, Xiao-Jiang Zhou1, Nong-Hua Lv1.   

Abstract

AIM: To access the efficacy of combination with amoxicillin and tetracycline for eradication of Helicobacter pylori (H. pylori), thus providing clinical practice guidelines.
METHODS: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Science Citation Index, China National Knowledge Infrastructure, Wanfang, and Chinese Biomedical Literature databases and abstract books of major European, American, and Asian gastroenterological meetings were searched. All clinical trials that examined the efficacy of H. pylori eradication therapies and included both tetracycline and amoxicillin in one study arm were selected for this systematic review and meta-analysis. Statistical analysis was performed with Comprehensive Meta-Analysis Software (Version 2). Subgroup, meta-regression, and sensitivity analyses were also carried out.
RESULTS: Thirty-three studies met the inclusion criteria. The pooled odds ratio (OR) was 0.90 (95%CI: 0.42-1.78) for quadruple therapy with amoxicillin and tetracycline vs other quadruple regimens, and total eradication rates were 78.1% by intention-to-treat (ITT) and 84.5% by per-protocol (PP) analyses in the experimental groups. The pooled eradication rates of 14-d quadruple regimens with a combination of amoxicillin and tetracycline were 82.3% by ITT and 89.0% by PP, and those of 10-d regimens were 84.6% by ITT and 93.7% by PP. The OR by ITT were 1.21 (95%CI: 0.64-2.28) for triple regimens with amoxicillin and tetracycline vs other regimens and 1.81 (95%CI: 1.37-2.41) for sequential treatment with amoxicillin and tetracycline vs other regimens, respectively.
CONCLUSION: The effectiveness of regimens employing amoxicillin and tetracycline for H. pylori eradication may be not inferior to other regimens, but further study should be necessary.

Entities:  

Keywords:  Amoxicillin; Helicobacter pylori; Meta-analysis; Systemic review; Tetracycline

Mesh:

Substances:

Year:  2015        PMID: 25741163      PMCID: PMC4342932          DOI: 10.3748/wjg.v21.i8.2522

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  52 in total

Review 1.  Clinical practice. Helicobacter pylori infection.

Authors:  Kenneth E L McColl
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.

Authors:  Jun-Won Chung; Jeong Hoon Lee; Hwoon-Yong Jung; Sung-Cheol Yun; Tae-Hoon Oh; Kee Don Choi; Ho June Song; Gin Hyug Lee; Jin-Ho Kim
Journal:  Helicobacter       Date:  2011-08       Impact factor: 5.753

4.  Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.

Authors:  Jae Hee Cheon; Sang Gyun Kim; Jung Mogg Kim; Nayoung Kim; Dong Ho Lee; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

5.  High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Authors:  Qinjuan Sun; Xiao Liang; Qing Zheng; Wenzhong Liu; Shudong Xiao; Weiqi Gu; Hong Lu
Journal:  Helicobacter       Date:  2010-06       Impact factor: 5.753

6.  The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication.

Authors:  Murat Akyildiz; Sinan Akay; Ahmet Musoglu; Muge Tuncyurek; Ahmet Aydin
Journal:  Eur J Intern Med       Date:  2008-06-10       Impact factor: 4.487

7.  Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

Authors:  Jyh-Ming Liou; Chieh-Chang Chen; Chi-Yang Chang; Mei-Jyh Chen; Yu-Jen Fang; Ji-Yuh Lee; Chien-Chuan Chen; Shih-Jer Hsu; Yao-Chun Hsu; Cheng-Hao Tseng; Ping-Huei Tseng; Lawrence Chang; Wen-Hsiung Chang; Hsiu-Po Wang; Chia-Tung Shun; Jeng-Yih Wu; Yi-Chia Lee; Jaw-Town Lin; Ming-Shiang Wu
Journal:  J Antimicrob Chemother       Date:  2012-10-25       Impact factor: 5.790

8.  Preservation of gastric antral mucus is associated with failure of eradication of Helicobacter pylori by bismuth, metronidazole and tetracycline.

Authors:  A J Lobo; C A McNulty; J S Uff; J Dent; I A Eyre-Brook; S P Wilkinson
Journal:  Aliment Pharmacol Ther       Date:  1994-04       Impact factor: 8.171

9.  Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand.

Authors:  Ratha-Korn Vilaichone; Pornpen Gumnarai; Thawee Ratanachu-Ek; Varocha Mahachai
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-04       Impact factor: 2.803

10.  Poor efficacy of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori eradication.

Authors:  Ahmet Uygun; Abdurrahman Kadayifci; Zeki Yesilova; Yuksel Ates; Mukerrem Safali; Seyfettin Ilgan; Sait Bagci; Kemal Dagalp
Journal:  Indian J Gastroenterol       Date:  2007 Jul-Aug
View more
  8 in total

Review 1.  Antimicrobial hydrogels: promising materials for medical application.

Authors:  Kerong Yang; Qing Han; Bingpeng Chen; Yuhao Zheng; Kesong Zhang; Qiang Li; Jincheng Wang
Journal:  Int J Nanomedicine       Date:  2018-04-12

2.  Progresses about the Interplay among Clarithromycin, Immune and Central Nervous Systems.

Authors:  Ester di Giacomo; Enrico Biagi; Fabrizia Colmegna; Flora Aspesi; Antonios Dakanalis; Maria Fotiadou; Massimo Clerici
Journal:  J Neuroimmune Pharmacol       Date:  2017-08-01       Impact factor: 4.147

Review 3.  Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.

Authors:  Jun-Hyung Cho; So-Young Jin
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

4.  Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections.

Authors:  Tiankuo Yang; Renwei Hu; Xiaoqiong Tang; Yalin Shen; Alfred Tay; Xuenan Pi; Gang Wang; Aleksandra W Debowski; Keith A Stubbs; Mohammed Benghezal; Barry J Marshall; Hong Li; Hong Tang
Journal:  Precis Clin Med       Date:  2020-03-17

Review 5.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

Review 6.  Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis.

Authors:  Yiqiao Xin; Jan Manson; Lindsay Govan; Robin Harbour; Jenny Bennison; Eleanor Watson; Olivia Wu
Journal:  BMC Gastroenterol       Date:  2016-07-26       Impact factor: 3.067

7.  Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.

Authors:  Ju Yup Lee; Nayoung Kim; Kyung Sik Park; Hyun Jin Kim; Seon Mee Park; Gwang Ho Baik; Ki-Nam Shim; Jung Hwan Oh; Suck Chei Choi; Sung Eun Kim; Won Hee Kim; Seon-Young Park; Gwang Ha Kim; Bong Eun Lee; Yunju Jo; Su Jin Hong
Journal:  BMC Gastroenterol       Date:  2016-07-26       Impact factor: 3.067

8.  Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.

Authors:  Junxian Wang; Yuping Cao; Wei He; Xiaoping Li
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.